Victoria 2 stockpile buy sell11/3/2022 ![]() VICTORIA 2 STOCKPILE BUY SELL FREEThe Australian Council of Trade Unions secretary Liam O'Brien called for rapid antigen tests to be made free for all workers, particularly those at small- and medium-sized businesses. On average, research analysts predict that ACADIA Pharmaceuticals will post -1.Rapid antigen tests only became available for purchase in supermarkets and chemists in November. During the same quarter last year, the company posted ($0.27) EPS. The company's quarterly revenue was up 16.8% compared to the same quarter last year. ACADIA Pharmaceuticals had a negative net margin of 39.93% and a negative return on equity of 41.18%. The firm had revenue of $134.56 million during the quarter, compared to analysts' expectations of $130.06 million. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. The firm has a 50-day moving average price of $15.98 and a two-hundred day moving average price of $18.76.ĪCADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating) last posted its quarterly earnings data on Monday, August 8th. ACADIA Pharmaceuticals has a 1-year low of $12.24 and a 1-year high of $28.06. The stock has a market capitalization of $2.90 billion, a PE ratio of -14.10 and a beta of 0.67. ACADIA Pharmaceuticals Trading Up 3.0 %ĪCAD opened at $17.91 on Tuesday. Based on data from, the company currently has an average rating of "Hold" and an average price target of $22.72. One analyst has rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company. Finally, Royal Bank of Canada lowered their price target on shares of ACADIA Pharmaceuticals from $26.00 to $21.00 and set an "outperform" rating for the company in a research report on Tuesday, August 9th. Mizuho lowered their price target on shares of ACADIA Pharmaceuticals from $27.00 to $19.00 and set a "neutral" rating for the company in a research report on Tuesday, August 9th. cut shares of ACADIA Pharmaceuticals from an "overweight" rating to a "neutral" rating in a research report on Tuesday, June 21st. HC Wainwright lifted their price target on shares of ACADIA Pharmaceuticals from $20.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, August 9th. Jefferies Financial Group cut shares of ACADIA Pharmaceuticals from a "buy" rating to an "underperform" rating and lowered their price target for the stock from $25.00 to $10.00 in a research report on Tuesday, June 21st. Several other brokerages have also recently commented on ACAD. 7 Dividend Aristocrats to Help You Take the Bite Out of the BearĪCADIA Pharmaceuticals ( NASDAQ:ACAD - Get Rating) was downgraded by research analysts at from a "buy" rating to a "hold" rating in a report issued on Tuesday.10 Recession-Proof Stocks That Will Let You Wait Out the Bear.7 Stocks with the Pricing Power to Push Through High Inflation.7 Blue-Chip Dividend Stocks That Won’t be Impacted by Rising Interest Rates.7 Mid-Cap Stocks That Can be the Perfect Fit at Any Time.7 Stocks to Buy to Outrun Rising Interest Rates.7 Sports Betting Stocks to Buy for Their Long-Term Possibilities.7 Water Stocks to Buy as the World Dries Up.7 Solar Stocks Leading the Clean Energy Boom. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |